For research use only. Not for therapeutic Use.
Renzapride（Cat No.:M025304）is a novel gastrointestinal prokinetic agent with dual action as a serotonin 5-HT4 receptor agonist and a 5-HT3 receptor antagonist. It is primarily researched for its potential in treating irritable bowel syndrome (IBS) and other gastrointestinal motility disorders. By enhancing gut motility and reducing visceral sensitivity, Renzapride offers symptomatic relief from constipation and abdominal discomfort associated with IBS. Its high specificity and efficacy ensure reliable results in clinical trials, making it a promising candidate for developing new treatments for gastrointestinal conditions and improving patients’ quality of life.
| Catalog Number | M025304 |
| CAS Number | 112727-80-7 |
| Synonyms | 4-amino-N-[(4S,5R)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide |
| Molecular Formula | C16H22ClN3O2 |
| Purity | ≥95% |
| IUPAC Name | 4-amino-N-[(4R,5S)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide |
| InChI | InChI=1S/C16H22ClN3O2/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-14-4-6-20-5-2-3-10(14)9-20/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21)/t10-,14+/m0/s1 |
| InChIKey | GZSKEXSLDPEFPT-IINYFYTJSA-N |
| SMILES | COC1=CC(=C(C=C1C(=O)NC2CCN3CCCC2C3)Cl)N |
